Human Microbiome Sequencing Market Top Players - Baseclear B.V., Beijing Genomics Institute (BGI) Genomics Co., Ltd, Charles River Laboratories International Inc., Clinical Microbiomics A/S, Eurofins Scientific SE.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Human Microbiome Sequencing Market by (Product Type (Kits And Assays, Instruments, And Software), Technology (Sequencing By Synthesis, Sequencing By Ligation And Other Next-Generation Sequencing Technologies), Traditional Sequencing Technologies (Pyrosequencing And Sanger Sequencing) And Other Sequencing Technology. Application (Disease Diagnosis (Gastrointestinal Diseases, Metabolic Diseases, Oncology, Infectious Diseases, Neurological Diseases And Other Diseases), Drug Discovery, Consumer Wellness, Omics Analysis (Genome Analysis, Metabolome Analysis, Transcriptome Analysis And Other Omics Analysis) And Other Application), End-User (Research And Academic Institutions, Pharmaceutical And Biotechnology Companies, And Other End Users) - Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

The global human microbiome sequencing market is estimated to exhibit a CAGR of 20.8% during the forecast period.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1380

The "human microbiome" refers to the diverse ecosystem of microorganisms, including bacteria, bacteriophages, fungi, protozoa, and viruses, that reside within the human body. These microbial cells outnumber human cells by a factor of ten and contribute approximately 2-3 kilograms to body weight. The human microbiome sequencing market is experiencing robust growth, driven by advancements in genomics, proteomics, and metabolomics, as well as the continued evolution of next-generation sequencing (NGS) technologies. Furthermore, the increasing emphasis on human microbiome-based therapies as a promising avenue for treatment is further stimulating market expansion.

The demand for human microbiome sequencing is being bolstered by its expanding applications in early disease detection and diagnosis, coupled with the reduction in sequencing costs. The market is also benefiting from a rise in research collaborations, increased funding for microbiome-focused studies, and the growing need for investigational new drug (IND) applications, particularly for fecal microbiota. Additionally, the global expansion of genomic research is fueling the anticipated growth of the human microbiome sequencing market, supported by an uptick in genomic research and development initiatives.

List of Prominent Players in the Human Microbiome Sequencing Market:
• Baseclear B.V.
• Beijing Genomics Institute (BGI) Genomics Co., Ltd
• Charles River Laboratories International Inc.
• Clinical Microbiomics A/S
• Eurofins Scientific SE
• GENEWIZ, Inc.
• Illumina, Inc.
• Novogene Corporation
• OraSure Technologies, Inc.
• Oxford Nanopore Technologies, Inc.
• Pacific Biosciences of California, Inc.
• QIAGEN N.V.
• Second Genome, Inc.
• Thermo Fisher Scientific Inc.
• Viome, Inc.
• CosmosID
• Leucine Rich Bio Pvt. Ltd.
• Microba
• Microbiome Insights Inc.
• Molzym GmbH & Co. KG

Market Dynamics:
Drivers-
The human gut microbiota plays a crucial role in optimizing the efficacy of pharmaceutical treatments. Research has shown that maintaining a balanced microbial environment within the body can significantly contribute to the treatment of various diseases. The link between specific microbial populations and disease conditions creates new avenues for the development of drugs and vaccines. Microorganisms also serve as valuable sources of enzymes, which are instrumental in therapeutic applications, especially in the discovery of innovative treatments. With numerous small, innovative companies driving advancements in the field, substantial growth opportunities exist for major industry players to acquire these entities, thereby advancing microbiome research and the discovery of new drug targets for conditions such as obesity, liver diseases, diabetes, and metabolic disorders. Strategic partnerships and collaborations are increasingly being prioritized by leading market participants to expand their product portfolios through enhanced research and development initiatives.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-01

Challenges:
Probiotics have yet to receive approval from the FDA as live biotherapeutic products, which are biological products containing living organisms used for the treatment or prevention of human diseases, excluding vaccines. While probiotic-containing foods and dietary supplements are FDA-regulated and legally marketed, they are not authorized for use in treating, preventing, or mitigating illnesses. The FDA is currently evaluating potential revisions to its regulatory framework for probiotics. Moreover, genetically engineered microorganisms may face unique regulatory challenges. Additionally, current methodologies for identifying microbial indicators for diagnostic purposes require comparison with control groups of healthy individuals to ensure their accuracy. Selecting the most appropriate microbe for specific therapeutic applications remains a significant challenge, complicating the process of choosing the ideal microbial chassis for microbiota-based treatments.

Regional Trends:
North America continues to dominate the human microbiome sequencing market, driven by the region's robust healthcare infrastructure, substantial investments from key companies in developing innovative devices, drug development, and research initiatives. This dominance is further bolstered by advancements in next-generation sequencing (NGS) technologies and the rising prevalence of lifestyle-related health conditions. For example, Illumina Inc., a prominent American company, has highlighted that innovations in NGS have facilitated significant collaborative efforts, such as the Human Microbiome Project and MetaHIT, both of which have utilized NGS as a core tool for generating comprehensive human microbiome data. In contrast, the Asia-Pacific region is projected to experience substantial growth during the forecast period, driven by the expansion of related research institutions, a growing focus on microbiome research, and an increasing prevalence of lifestyle-related diseases. The region's market growth is further fueled by heightened awareness of preventive healthcare, increased funding for microbiome studies, and the expansion of research and clinical activities related to the microbiome.

Recent Developments:
• In September 2021, PhenoBiome announced that its first human gut microbiome assay would be available through Genetic Direction, a Dallas-based distributor of genetics-based health management solutions. Clinical Enterprise, Inc., a Eurofins Scientific subsidiary, will perform the assays in its CLIA- and CAP-certified laboratory.
• In July 2021, Seres Therapeutics Inc. and Nestlé Health Science agreed to collaborate on the commercialization of SER-109, an experimental oral microbiome treatment for recurrent Clostridioides difficile infection (CDI), in the United States (U.S.) and Canada. If it is approved, SER-109 will be the first FDA-approved microbiome treatment.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1380

Segmentation of Human Microbiome Sequencing Market-
By Product Type
• Kits and Assays
• Instruments
• Software
By Technology
• Next-Generation Sequencing
o Sequencing by Synthesis
o Sequencing by Ligation
o Other Next-Generation Sequencing Technologies
• Traditional Sequencing Technologies
o Pyrosequencing
o Sanger Sequencing
• Other Sequencing Technology
By Application
• Disease Diagnoses
o Gastrointestinal Diseases
o Metabolic Diseases
o Oncology
o Infectious Diseases
o Neurological Diseases
o Other Diseases
• Drug Discovery
• Consumer Wellness
• Omics Analysis
o Genome Analysis
o Metabolome Analysis
o Transcriptome Analysis
o Other Omics Analysis
• Other Application
By End User
• Research and Academic Institutions
• Pharmaceutical and Biotechnology Companies
• Other End Users
By Region-
• North America-
o US
o Canada
o Mexico
• Europe-
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• Asia-Pacific-
o China
o Japan
o India
o South Korea
o South East Asia
o Rest of Asia Pacific
• Latin America-
o Brazil
o Argentina
o Rest of Latin America
• Middle East & Africa-
o GCC Countries
o South Africa
o Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/global-human-microbiome-sequencing-market/1380

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.